Rekord LOINC: 62986-5
Tylko wersja angielska DISCOURAGED
Szczegóły rekordu LOINC
Informacje podstawowe
| Kod LOINC: |
62986-5
FHIR
|
| Long Common Name: | PhenX - grammatical impairments - clinical evaluation of language fundamentals protocol 200501 |
| Short Name: | Grammat impair - eval lang proto |
| Status: | DISCOURAGED |
| Class Type: | 2 |
Fully Specified Name (FSN)
EN
Oryginalna wersja angielska
PhenX - grammatical impairments - clinical evaluation of language fundamentals protocol 200501
:
-
:
Pt
:
^Patient
:
-
:
PhenX
Klasyfikacja
| Class: |
ENPANEL.PHENX
|
| Consumer Name: | - |
| Order/Observation: | - |
| Panel Type: | - |
Informacje dodatkowe
| Units Required: | N |
| Example Units: | - |
| UCUM Units: | - |
| Version Last Changed: | 2.81 |
Definicja i opis
EN
The Recalling Sentences subtest of the Clinical Evaluation of Language Fundamentals®, Fourth Edition (CELF® - 4) is an interviewer-administered test that determines if a student has a language disorder or delayed language development. It asks a student to imitate sentences presented by the examiner. As the test progresses, the sentences become longer and more complex. Respondents are scored for the number of errors made in each sentence. The Clinical Evaluation of Language Fundamentals®, Fourth Edition (CELF® - 4) can be scored using the CELF®-4 Scoring Assistant (purchased separately). The Clinical Evaluation of Language Fundamentals® is a proprietary instrument. Each Clinical Evaluation of Language Fundamentals® subtest is a part of a complete assessment and is not sold separately. To administer/use a subtest requires a licensing agreement from Pearson. Researchers should complete and return an application to pas.licensing@pearson.com. In order for this assessment to be considered valid, the investigator should make sure that the respondent speaks English as a first language. For genetic studies children should be assessed for hearing or nonverbal cognitive impairment as related factors. Although the Clinical Evaluation of Language Fundamentals® is validated for children, adolescents and adults, ages 5-21 years, the Speech and Hearing Working Group recommends that it be used only for adolescents and adults ages 15-21 years.
Powiązane nazwy
Assessment; Eval; Grammat impair - eval lang proto; H&P; History and physical; Pan; Panel; PANEL.PHENX; Panl; Pnl; Point in time; Random